Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)

SHA:603392 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,781	2,388	3,819	5,193	1,416	710.67
Short-Term Investments	1,160	480	-	-	200	52.54
Trading Asset Securities	2,067	2,510	2,055	2,009	40.39	50.36
Cash & Short-Term Investments	5,008	5,378	5,874	7,201	1,656	813.57
Cash Growth	-10.85%	-8.44%	-18.43%	334.83%	103.56%	134.46%
Accounts Receivable	1,803	2,064	2,999	3,960	2,277	711.6
Other Receivables	99.55	35.96	48.71	5.15	12.45	13.04
Receivables	1,907	2,104	3,053	3,970	2,292	724.64
Inventory	947	863.19	905.48	869.14	593.17	400.04
Prepaid Expenses	0.24	-	-	-	-	-
Other Current Assets	39.47	29.44	469.42	139.4	105.2	39.54
Total Current Assets	7,902	8,375	10,302	12,180	4,647	1,978
Property, Plant & Equipment	3,552	3,538	2,641	2,235	1,703	790.98
Long-Term Investments	1,222	1,362	12.01	911.3	61.3	211.3
Other Intangible Assets	819.95	512.46	508.28	292.5	289.92	226.66
Long-Term Deferred Tax Assets	251.52	243.33	157.95	66.01	68.97	56.49
Long-Term Deferred Charges	180.58	363.85	214.29	172.37	27.18	27.76
Other Long-Term Assets	312.25	294.67	1,879	372.3	249.09	212.7
Total Assets	14,241	14,689	15,715	16,230	7,046	3,504
Accounts Payable	172.64	137.94	234.28	275.47	154.08	107.29
Accrued Expenses	832.37	915.89	1,653	2,572	1,541	440.8
Short-Term Debt	120.16	103.62	81.14	140.14	235.64	77.66
Current Portion of Long-Term Debt	22.61	65.68	87.19	3.07	-	-
Current Portion of Leases	38.63	38.43	13.3	13.73	13.93	-
Current Income Taxes Payable	0.11	8.59	7.49	99.02	146.55	4.37
Current Unearned Revenue	47.33	48.15	70.38	82.28	70.3	40.92
Other Current Liabilities	492.28	693.76	523.42	299.34	204.64	157.98
Total Current Liabilities	1,726	2,012	2,670	3,485	2,366	829.03
Long-Term Debt	88.22	94.19	115.36	102.49	4.9	-
Long-Term Leases	63.5	80.97	12.36	18.43	32.59	-
Long-Term Unearned Revenue	60.21	54.2	33.65	41.37	76.44	94.26
Long-Term Deferred Tax Liabilities	-	-	-	17.15	-	-
Other Long-Term Liabilities	-	-	-	-	3.8	-
Total Liabilities	1,938	2,241	2,831	3,665	2,483	923.29
Common Stock	1,265	1,265	1,268	906.07	607.04	433.6
Additional Paid-In Capital	3,139	3,139	3,312	3,729	445.83	446.27
Retained Earnings	7,806	7,950	8,250	7,906	3,413	1,674
Treasury Stock	-92.17	-92.17	-129.42	-200.17	-	-
Total Common Equity	12,119	12,263	12,701	12,341	4,466	2,554
Minority Interest	183.7	185.16	183.06	223.63	96.2	26.73
Shareholders' Equity	12,302	12,448	12,884	12,565	4,562	2,580
Total Liabilities & Equity	14,241	14,689	15,715	16,230	7,046	3,504
Total Debt	333.11	382.91	309.35	277.86	287.06	77.66
Net Cash (Debt)	4,675	4,995	5,565	6,923	1,369	735.91
Net Cash Growth	-12.78%	-10.23%	-19.63%	405.71%	86.03%	125.74%
Net Cash Per Share	3.43	3.76	4.42	5.54	1.11	0.62
Filing Date Shares Outstanding	1,265	1,265	1,268	1,268	1,232	1,232
Total Common Shares Outstanding	1,265	1,265	1,268	1,268	1,232	1,232
Working Capital	6,176	6,363	7,632	8,695	2,281	1,149
Book Value Per Share	9.58	9.69	10.01	9.73	3.62	2.07
Tangible Book Value	11,299	11,750	12,192	12,049	4,176	2,327
Tangible Book Value Per Share	8.93	9.29	9.61	9.50	3.39	1.89
Buildings	780.04	779.65	724.87	628.89	392.67	253.3
Machinery	1,960	1,764	1,510	1,185	666.87	565.97
Construction In Progress	1,415	1,469	814.56	720.51	924.38	231.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.